Lake Street Capital Comments on AxoGen Inc.’s FY2018 Earnings (AXGN)
AxoGen Inc. (NASDAQ:AXGN) – Equities research analysts at Lake Street Capital issued their FY2018 earnings per share estimates for shares of AxoGen in a research note issued to investors on Wednesday. Lake Street Capital analyst B. Jackson expects that the brokerage will post earnings per share of $0.10 for the year. Lake Street Capital has a “Buy” rating and a $11.00 price objective on the stock.
AxoGen (NASDAQ:AXGN) last issued its quarterly earnings results on Wednesday, November 2nd. The company reported ($0.08) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.08). AxoGen had a negative net margin of 33.02% and a negative return on equity of 292.94%.
A number of other equities research analysts also recently issued reports on the stock. Wedbush reaffirmed an “outperform” rating and set a $12.00 price target on shares of AxoGen in a research note on Friday. JMP Securities reissued a “buy” rating on shares of AxoGen in a research note on Tuesday, November 22nd.
Shares of AxoGen (NASDAQ:AXGN) remained flat at $8.45 on Monday. 158,291 shares of the stock were exchanged. The stock’s 50 day moving average price is $8.66 and its 200-day moving average price is $7.71. The firm’s market cap is $277.99 million. AxoGen has a one year low of $4.52 and a one year high of $9.88.
Hedge funds and other institutional investors have recently bought and sold shares of the company. UBS Group AG boosted its position in AxoGen by 991.7% in the first quarter. UBS Group AG now owns 97,946 shares of the company’s stock worth $525,000 after buying an additional 88,974 shares during the last quarter. Bank of New York Mellon Corp boosted its position in AxoGen by 196.8% in the second quarter. Bank of New York Mellon Corp now owns 80,580 shares of the company’s stock worth $555,000 after buying an additional 53,427 shares during the last quarter. California State Teachers Retirement System bought a new position in AxoGen during the second quarter worth approximately $348,000. Nationwide Fund Advisors bought a new position in AxoGen during the second quarter worth approximately $105,000. Finally, Vanguard Group Inc. boosted its position in AxoGen by 61.5% in the second quarter. Vanguard Group Inc. now owns 775,448 shares of the company’s stock worth $5,335,000 after buying an additional 295,294 shares during the last quarter. Hedge funds and other institutional investors own 52.42% of the company’s stock.
In related news, VP John P. Engels purchased 4,000 shares of the business’s stock in a transaction dated Friday, October 7th. The shares were purchased at an average cost of $7.50 per share, for a total transaction of $30,000.00. Following the completion of the acquisition, the vice president now owns 98,425 shares in the company, valued at approximately $738,187.50. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Karen L. Zaderej purchased 10,000 shares of the business’s stock in a transaction dated Friday, October 7th. The stock was bought at an average price of $7.50 per share, for a total transaction of $75,000.00. Following the completion of the acquisition, the chief executive officer now owns 242,147 shares of the company’s stock, valued at approximately $1,816,102.50. The disclosure for this purchase can be found here. 9.33% of the stock is currently owned by insiders.
Receive News & Stock Ratings for AxoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen Inc. and related stocks with our FREE daily email newsletter.